Euro area vs Lesotho: Access to anti-retroviral drugs, female
Euro area
88.6%
in 2022
Lesotho
98.0%
in 2024
Euro area rank
2nd
Lesotho rank
1st
Access to anti-retroviral drugs, female over time
- Euro area
- Lesotho
How they compare
Lesotho currently reports 98.0% against 88.6% in Euro area, a difference of 9.4%.
That makes Lesotho's figure about 1.1 times Euro area's.
The two have swapped places 1 time across 23 shared years of data; in 2000 it was Euro area ahead.
Euro area ranks 2nd and Lesotho ranks 1st of 19 groups.
Across the 3 decades both report, Euro area averaged higher in 2 and Lesotho in 1.
Head to head by decade
| Decade | Euro area | Lesotho | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 59.4% | 7.8% | 51.6% | Euro area |
| 2010s | 81.4% | 55.4% | 26.0% | Euro area |
| 2020s | 87.5% | 88.0% | 0.5% | Lesotho |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Euro area or Lesotho?
- Lesotho, at 98.0% against 88.6% in Euro area as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Euro area and Lesotho?
- 9.4%, with Lesotho ahead.
- How many years of comparable data are there for Euro area and Lesotho?
- 23 years are reported by both, from 2000 to 2022.
- How do Euro area and Lesotho rank globally for access to anti-retroviral drugs, female?
- Euro area ranks 2nd and Lesotho ranks 1st of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.